AbbVie's third successful Parkinson's trial sets the stage for an eventful 2025
AbbVie Inc. announced positive data from a third late-stage trial of a treatment for Parkinson's disease on Monday and said it's on track to seek approval for the drug from the Food and Drug Admini...
AbbVie's Parkinson's disease drug meets main goal in late-stage study
AbbVie said on Monday its experimental drug to treat Parkinson's disease met the main goal in a late-stage study.
AbbVie Announces Emotional Impact Report on Mental Health of Underrepresented CLL Cancer Patients
-New insights show Black, Hispanic, and Asian patients have more negative emotional experiences and outlooks with their chronic lymphocytic leukemia (CLL) diagnosis and treatment journeys -CLL is o...
Investigational Epcoritamab (DuoBody® CD3xCD20) Combination Therapy Shows High Response Rates in Clinical Trial of Patients With Relapsed or Refrac...
Data presented at the 66th Annual Meeting and Exposition of the American Society of Hematology (ASH) NORTH CHICAGO, Ill. , Dec. 7, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced updated r...
3 High-Yield Dividend Growth Stocks to Buy in December and Hold for a Decade or Longer
It's been a great couple of years for the stock market. From the end of 2022 through Nov. 29, the benchmark S&P 500 (^GSPC 0.24%) index rose a whopping 57.1% higher.
3 Fantastic Dividend Stocks to Buy Sooner Rather Than Later
You don't have to be an income investor to like dividends. Many billionaires who definitely don't need income still have dividend stocks in their portfolios.
2 High-Yield Dividend Stocks to Buy Now for a Lifetime of Passive Income
Investors looking for a way to pump up their passive income streams want to turn their attention toward the pharmaceutical industry. From the end of 2022 through Nov. 22, the benchmark S&P 500 inde...
One Sector Has Underperformed Massively: These 4 Blue-Chip Dividend Giants Are Huge 2025 Plays
Key Points Donald Trump's victory is positive for the stock market.
Dividend Aristocrats Yielding Over 4% to Buy in November
Companies with high dividend yields are relatively uncommon in this market.
The Stock Market Is Soaring but These 2 Stocks Are Still Dirt Cheap Buys
Earlier this month, the S&P 500 hit a record high of more than 6,000 for the first time ever. Based on that, you might assume that stocks may be too expensive to buy right now as the average stock ...
3 Dividend Stocks That Are Screaming Buys in November
Political uncertainty has created buying opportunities among blue-chip healthcare stocks with big-time dividends.
AbbVie: Upgrading To 'Strong Buy' After Pullback
In recent days, financial market participants have remained pessimistic about AbbVie's prospects, mainly due to the data on clinical outcomes related to emraclidine. However, I believe Mr. Market o...
AbbVie's Ovarian Cancer Drug Elahere Gets Approval in Europe
The European Commission approves ABBV's Elahere for the treatment of platinum-resistant ovarian cancer.
AbbVie Receives European Commission Approval of ELAHERE® (mirvetuximab soravtansine) for the Treatment of Platinum-Resistant Ovarian Cancer
ELAHERE is the first and only novel therapy approved in the European Union specifically for patients with folate receptor-alpha (FRα) positive, platinum-resistant ovarian cancer ELAHERE represents ...
Got $1,500 to Invest? AbbVie Just Proved the Bull Thesis for Its Stock
The drugmaker has convincingly laid to rest the biggest threat to its top line.
Related Companies